PMID- 19429089
OWN - NLM
STAT- MEDLINE
DCOM- 20090715
LR  - 20221207
IS  - 1872-7972 (Electronic)
IS  - 0304-3940 (Linking)
VI  - 454
IP  - 3
DP  - 2009 May 1
TI  - Inhibitory effect of selective serotonin reuptake inhibitors on the vesicular 
      monoamine transporter 2.
PG  - 229-32
LID - 10.1016/j.neulet.2009.03.049 [doi]
AB  - The neuronal vesicular monoamine transporter (VMAT2) is the target molecule of 
      action of some psychostimulants, such as methamphetamine and 
      3,4-methylenedioxymethamphetamine (MDMA). The present study examined the effect 
      of antidepressants, such as selective serotonin reuptake inhibitors (SSRIs), on 
      VMAT2 activity by measuring adenosine triphosphate-dependent [(3)H]dopamine 
      uptake into synaptic vesicles prepared from rat striatum. SSRIs, fluoxetine, 
      paroxetine, and fluvoxamine, inhibited vesicular [(3)H]dopamine uptake in vitro. 
      The rank order of potency was reserpine>>fluoxetine, paroxetine>fluvoxamine, 
      methamphetamine>MDMA. Moreover, kinetic analysis revealed that inhibition by 
      reserpine, a typical VMAT2 inhibitor, was uncompetitive, decreasing maximum 
      velocity and affinity for dopamine. Inhibition by fluoxetine was noncompetitive, 
      only decreasing maximum velocity for dopamine. These results suggest that 
      fluoxetine inhibited the activity of VMAT2 by a mechanism different from that of 
      reserpine and did not directly interact with the active site of VMAT2.
FAU - Yasumoto, Satoshi
AU  - Yasumoto S
AD  - Division of Psychobiology, Tokyo Institute of Psychiatry, 2-1-8 Kamikitazawa, 
      Setagaya-ku, Tokyo 156-8585, Japan.
FAU - Tamura, Kohei
AU  - Tamura K
FAU - Karasawa, Junichi
AU  - Karasawa J
FAU - Hasegawa, Ryota
AU  - Hasegawa R
FAU - Ikeda, Kazutaka
AU  - Ikeda K
FAU - Yamamoto, Toshifumi
AU  - Yamamoto T
FAU - Yamamoto, Hideko
AU  - Yamamoto H
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20090318
PL  - Ireland
TA  - Neurosci Lett
JT  - Neuroscience letters
JID - 7600130
RN  - 0 (Serotonin Uptake Inhibitors)
RN  - 0 (Slc18a2 protein, rat)
RN  - 0 (Vesicular Monoamine Transport Proteins)
RN  - 01K63SUP8D (Fluoxetine)
RN  - 41VRH5220H (Paroxetine)
RN  - 44RAL3456C (Methamphetamine)
RN  - 8B1QWR724A (Reserpine)
RN  - J6292F8L3D (Haloperidol)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
RN  - O4L1XPO44W (Fluvoxamine)
RN  - VTD58H1Z2X (Dopamine)
SB  - IM
MH  - Animals
MH  - Dopamine/metabolism
MH  - Fluoxetine/pharmacology
MH  - Fluvoxamine/pharmacology
MH  - Haloperidol/pharmacology
MH  - Male
MH  - Methamphetamine/pharmacology
MH  - N-Methyl-3,4-methylenedioxyamphetamine/pharmacology
MH  - Paroxetine/pharmacology
MH  - Rats
MH  - Rats, Wistar
MH  - Reserpine/pharmacology
MH  - Selective Serotonin Reuptake Inhibitors/*pharmacology
MH  - Synaptic Vesicles/drug effects/metabolism
MH  - Vesicular Monoamine Transport Proteins/*drug effects/*metabolism
EDAT- 2009/05/12 09:00
MHDA- 2009/07/16 09:00
CRDT- 2009/05/12 09:00
PHST- 2008/10/24 00:00 [received]
PHST- 2009/03/06 00:00 [revised]
PHST- 2009/03/12 00:00 [accepted]
PHST- 2009/05/12 09:00 [entrez]
PHST- 2009/05/12 09:00 [pubmed]
PHST- 2009/07/16 09:00 [medline]
AID - S0304-3940(09)00332-2 [pii]
AID - 10.1016/j.neulet.2009.03.049 [doi]
PST - ppublish
SO  - Neurosci Lett. 2009 May 1;454(3):229-32. doi: 10.1016/j.neulet.2009.03.049. Epub 
      2009 Mar 18.